Inflammation Induced Bone Loss: Molecular Basis and Translational Research

Dear Colleagues,

Inflammation-induced bone loss is a key feature in rheumatoid arthritis which activates bone-resorbing osteoclast cells and suppresses osteoblast activity, which results in osteopenia/osteoporosis in patients. Nowadays, disease modified agents are inadequate to limit or prevent systemic and joint bone loss in rheumatoid arthritis (RA) patients. Antiresorptive therapeutic drugs, like bisphosphonate, limit bone loss by inhibiting osteoclast activity but have side effects like jaw osteonecrosis and atypical fracture. Osteoanabolic agents PTH (parathyroid hormone) and PTHrP (parathyroid hormone-related protein) promote the osteoblast function, but these agents are costly and may lead to osteosarcoma. Another anti-sclerostin antibody limits bone loss and increases cardiovascular disease or risk factors in patients. Thus, there is an urgent need to look for new therapeutic agents which limit systemic and joint bone loss without having side effects in inflammatory arthritis conditions.

This Special Issue welcomes original articles and reviews on inflammation-induced bone loss in the RA model.

Dr. Priyanka Kushwaha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• rheumatoid arthritis
• metabolism induced inflammation
• inflammasome
• osteoporosis
• molecular medicine
• disease biology
• bone diseases